Antibodies specific for CLL-1

Inventors

Jiang, Ping • KARSUNKY, Holger • Tressler, Rob

Assignees

Onk Therapeutics Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9850314-B2

Patent

Publication Date

2017-12-26

Expiration Date


Abstract

Provided herein are antibodies specific for CLL-1.

Core Innovation

The invention provides CLL-1-specific antibodies that bind to human C-type lectin like molecule 1 (CLL-1) and are described in the context of treating acute myeloid leukemia (AML). The disclosed antibodies are characterized by specific heavy chain CDRs and light chain CDRs defined by SEQ ID NO references, and the antibody binding to CLL-1 is described as broad for AML patient cells.

The invention further describes competitive binding behavior and epitope-domain preferences for the antibodies, including binding that involves stalk+C-lectin versus lectin alone. Multiple antibody clones are characterized, including M26, M31, and G4 (31.G4 / ChiG4), and additional chimeric human antibodies are described for these clones.

Functional activity is described including complement dependent cytotoxicity (CDC), antibody dependent cell-mediated cytotoxicity (ADCC), and antibody drug conjugate (ADC) activity using saporin. The invention also includes diagnostic uses for detecting CLL-1-expressing cells using labeled antibody binding detection, including in the context of evaluating CLL-1-expressing cell populations.

Claims Coverage

The provided independent claim covers one inventive feature: a CLL-1-binding antibody defined by specific heavy-chain and light-chain CDR sets, used for treating AML.

CDR-defined CLL-1-binding antibody for AML treatment

Administering to an individual an antibody that binds to human C-type lectin like molecule 1 (CLL-1), wherein the antibody is selected from antibodies comprising specified heavy chain CDRs and specified light chain CDRs defined by SEQ ID NOs, thereby treating acute myeloid leukemia (AML).

The core inventive limitation is the use of a human CLL-1-binding antibody defined by specific heavy-chain and light-chain CDR sequence sets for treating AML.

Stated Advantages

Broad binding to AML patient cells.

Functional activity described including CDC, ADCC, and ADC activity using saporin.

Documented Applications

Therapeutic treatment of acute myeloid leukemia (AML) in an individual by administering a CLL-1-binding antibody defined by specific heavy-chain and light-chain CDR sets.

Diagnostic detection of CLL-1-expressing cells using labeled antibody binding detection.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.